ARCHIVES

Senate confirms McClellan to head CMS. NCI “redeploys” $54.5 million cut from divisions to fund strategic initiatives.

This article is from The Cancer Letter archive.

Vol. 30 No. 13 | March 26, 2004

Download PDF Visit The Full Archive

Related Articles

NCI Cooperative Group, Cancer Center Trials Listed

October 31, 2008

Rall Supports Animal Tests; Carcinogenesis Reports Summarized

May 13, 1977

Latest Statistics Show Decline In Deaths From Breast Cancer

January 13, 1995

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

January 14, 2005

Cetuximab Plus Irinotecan Increases PFS In Metastatic Colorectal Cancer, EPIC Finds

April 27, 2007

Chemical Industry Sues NTP Over Listing PDC As Carcinogen; Environmental Groups Join Defense

June 23, 1989